Topic: Clinical Trial Results
Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.
Almost 30% of the participants were alive 18 months after starting treatment on a combination of CCX872 and the chemotherapy regimen FOLFIRINOX.
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
The IL-23 antibody easily outperformed J&J’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year.
The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.
The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.
The data tee Motif Bio up to file for approval of a drug that was knocked back by the FDA in 2009 and almost sunk the biotech 12 months ago.
The trial linked the single-domain antibody to a significant drop in time to platelet count response, bolstering Ablynx’s pitch for approval.
More than half of subjects who took the hydrogel particles lost weight, encouraging Gelesis to file for approval despite missing another endpoint.
Versartis’ somavaratan has failed to match Pfizer’s Genotropin in phase 3, wiping more than 80% off its stock price.